Dutch Health Care Insurance Board Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
1998
NCT00184977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Dutch Health Care Insurance Board (CVZ)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteritis (Phase 3)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Chronic Disease (Phase 4)

Collagen Diseases (Phase 3)

Colorectal Neoplasms (Phase 3)

Giant Cell Arteritis (Phase 3)

Granulomatosis with Polyangiitis (Phase 3)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Neoplasms (Phase 3)

Osteoporosis (Phase 3)

Peritoneal Neoplasms (Phase 3)

Polymyalgia Rheumatica (Phase 3)

Polymyositis (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Rheumatic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 11